Literature DB >> 26695061

Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update.

János Tajti1, Délia Szok1, Anett Csáti1, László Vécsei2,3.   

Abstract

Migraine as a highly disabling pain condition influences the daily activities of those affected, including children and adolescents. The pathomechanism of migraine is not fully understood, and the different types of prophylactic antimigraine drugs that are applied are not specific for migraine. There is a need for preventive treatment in the event of frequent migraine attacks, an impairment of the quality of life, severe accompanying or aura symptoms, and the failure of acute drug treatment. The following pharmacological classes are recommended: antidepressants, antiepileptics, antihistamines, beta-adrenergic receptor blockers, and calcium ion channel antagonists, besides onabotulinum toxin A and nutraceuticals (butterbur). The most urgent goal as concerns pharmaceutical innovation is the development of pathomechanism-based antimigraine drugs and personalized therapy tailored to the children and adolescents.

Entities:  

Keywords:  Antidepressants; Antiepileptics; Antihistamines; Beta-adrenergic receptor blockers; Butterbur; Calcium ion channel antagonists; Efficacy; Migraine; Onabotulinum toxin A; Pediatric; Prophylactic; Safety; Therapy; Tolerability

Mesh:

Substances:

Year:  2016        PMID: 26695061     DOI: 10.1007/s11916-015-0536-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  77 in total

Review 1.  Treatment of migraine with prophylactic drugs.

Authors:  Stefan Evers
Journal:  Expert Opin Pharmacother       Date:  2008-10       Impact factor: 3.889

Review 2.  Nutraceuticals in the prophylaxis of pediatric migraine: Evidence-based review and recommendations.

Authors:  Serena L Orr; Sunita Venkateswaran
Journal:  Cephalalgia       Date:  2014-01-17       Impact factor: 6.292

3.  [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].

Authors:  M K Bernhard; A Bertsche; S Syrbe; S Weise; A Merkenschlager
Journal:  Fortschr Neurol Psychiatr       Date:  2014-01-20       Impact factor: 0.752

Review 4.  Efficacy of antidepressants as analgesics: a review.

Authors:  Pinky Dharmshaktu; Vandana Tayal; Bhupinder Singh Kalra
Journal:  J Clin Pharmacol       Date:  2011-03-17       Impact factor: 3.126

5.  Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline.

Authors:  Tal Eidlitz-Markus; Yael Dlugatch; Yishai Haimi-Cohen; Hadassa Goldberg-Stern; Avraham Zeharia
Journal:  Pediatr Neurol       Date:  2012-06       Impact factor: 3.372

Review 6.  Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.

Authors:  D Lewis; S Ashwal; A Hershey; D Hirtz; M Yonker; S Silberstein
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

7.  Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients.

Authors:  Bernadett Tuka; Zsuzsanna Helyes; Adrienn Markovics; Teréz Bagoly; János Szolcsányi; Nikoletta Szabó; Eszter Tóth; Zsigmond Tamás Kincses; László Vécsei; János Tajti
Journal:  Cephalalgia       Date:  2013-04-18       Impact factor: 6.292

8.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

9.  Effective dose of topiramate in pediatric migraine prophylaxis.

Authors:  Ali Abbaskhanian; Hamid Reza Sadeghi; Ali Erfani; Mohammad Sadegh Rezai
Journal:  J Pediatr Neurosci       Date:  2012-09

10.  The efficacy and safety of topiramate for prophylaxis of migraine in children.

Authors:  Razieh Fallah; Sedighah Akhavan Karbasi; Ahmad Shajari; Mostafa Fromandi
Journal:  Iran J Child Neurol       Date:  2013
View more
  6 in total

1.  Experience of Botulinum Toxin A Injections for Chronic Migraine Headaches in a Pediatric Chronic Pain Clinic.

Authors:  Lisgelia Santana; Cherry Liu
Journal:  J Pediatr Pharmacol Ther       Date:  2021-02-15

Review 2.  Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials.

Authors:  Kai Le; Dafan Yu; Jiamin Wang; Abdoulaye Idriss Ali; Yijing Guo
Journal:  J Headache Pain       Date:  2017-07-18       Impact factor: 7.277

3.  Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients.

Authors:  Sameer S Ali; Ilya Bragin; Elizabeth Rende; Luis Mejico; Klaus E Werner
Journal:  Cureus       Date:  2019-03-29

4.  Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial.

Authors:  Shengyuan Yu; Ye Ran; Wei Xiao; Wenjing Tang; Jianjun Zhao; Wei Chen; Huikui Zhuang; Cun Ouyang; Hai Lin; Dequan Liu; Tongjun Chen; Hui Huang; Baoshen Wang; Yanlei Hao; Zhongrui Yan; Shike Zhao; Yanling Wang; Jinjun Ni; Chaodong Wang; Wentao Ding; Guoqian Li; Jianhua Cao; Shujuan Tian
Journal:  BMC Complement Altern Med       Date:  2019-12-16       Impact factor: 3.659

5.  L-carnitine versus Propranolol for pediatric migraine prophylaxis.

Authors:  Laya Amini; Omid Yaghini; Mohammadreza Ghazavi; Nahid Aslani
Journal:  Iran J Child Neurol       Date:  2021-03-01

Review 6.  Models for Treating Post-traumatic Headache.

Authors:  Joshua Kamins
Journal:  Curr Pain Headache Rep       Date:  2021-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.